This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Brixner D, Borisov N, Purple C.Excess medical cost after a fragility fracture during 3-year follow-up: Medicare perspective. 30th Annual Meeting of the American Society for Bone and Mineral Research: abstr. SA422, 12 Sep 2008. Available from: URL: http://www.asbmr.org
Gold D, Borisov N, Steinbuch M, Brixner D.Improvement in quality of life among women treated with risedronate: experience from a 2-year randomized controlled study. 30th Annual Meeting of the American Society for Bone and Mineral Research: abstr. SU414, 12 Sep 2008. Available from: URL: http://www.asbmr.org
Venkatachalam S, Suchitra R, Molloy C, McPeake J, Darrington S, Lloyd D, Price T.Quarterly intravenous ibandronic acid in the community setting in England - cost-effective healthcare delivery for osteoporosis patients. 30th Annual Meeting of the American Society for Bone and Mineral Research: abstr. SU409, 12 Sep 2008. Available from: URL: http://www.asbmr.org
Maggi S, Pasquale M, Bouin O.Modeled cost-effectiveness of risedronate versus ibandronate: the case of Italy. 30th Annual Meeting of the American Society for Bone and Mineral Research: abstr. SA426, 12 Sep 2008. Available from: URL: http://www.asbmr.org
Farquhar D, Pasquale M.Cost-effectiveness of risedronate versus ibandronate at one year: the case of the United Kingdom. 30th Annual Meeting of the American Society for Bone and Mineral Research: abstr. SA424, 12 Sep 2008. Available from: URL: http://www.asbmr.org
Rights and permissions
About this article
Cite this article
News from ASBMR. Pharmacoecon. Outcomes News 564, 7 (2008). https://doi.org/10.2165/00151234-200805640-00016
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805640-00016